{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,20]],"date-time":"2026-04-20T12:41:28Z","timestamp":1776688888190,"version":"3.51.2"},"reference-count":55,"publisher":"Springer Science and Business Media LLC","issue":"1","content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Transl Med"],"published-print":{"date-parts":[[2012,12]]},"abstract":"<jats:title>Abstract<\/jats:title>\n          <jats:sec>\n            <jats:title>Background<\/jats:title>\n            <jats:p>Inactivaion of tumor suppressor genes (TSGs) by promoter CpG methylation frequently occurs in tumorigenesis, even in the early stages, contributing to the initiation and progression of human cancers. <jats:italic>Deleted in lung and esophageal cancer 1<\/jats:italic> (<jats:italic>DLEC1<\/jats:italic>), located at the 3p22-21.3 TSG cluster, has been identified frequently silenced by promoter CpG methylation in multiple carcinomas, however, no study has been performed for lymphomas yet.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Methods<\/jats:title>\n            <jats:p>We examined the expression of <jats:italic>DLEC1<\/jats:italic> by semi-quantitative reverse transcription (RT)-PCR, and evaluated the promoter methylation of <jats:italic>DLEC1<\/jats:italic> by methylation-specific PCR (MSP) and bisulfite genomic sequencing (BGS) in common lymphoma cell lines and tumors.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Results<\/jats:title>\n            <jats:p>Here we report that <jats:italic>DLEC1<\/jats:italic> is readily expressed in normal lymphoid tissues including lymph nodes and PBMCs, but reduced or silenced in 70% (16\/23) of non-Hodgkin and Hodgkin lymphoma cell lines, including 2\/6 diffuse large B-cell (DLBCL), 1\/2 peripheral T cell lymphomas, 5\/5 Burkitt, 6\/7 Hodgkin and 2\/3 nasal killer (NK)\/T-cell lymphoma cell lines. Promoter CpG methylation was frequently detected in 80% (20\/25) of lymphoma cell lines and correlated with <jats:italic>DLEC1<\/jats:italic> downregulation\/silencing. Pharmacologic demethylation reversed <jats:italic>DLEC1<\/jats:italic> expression in lymphoma cell lines along with concomitant promoter demethylation. <jats:italic>DLEC1<\/jats:italic> methylation was also frequently detected in 32 out of 58 (55%) different types of lymphoma tissues, but not in normal lymph nodes. Furthermore, <jats:italic>DLEC1<\/jats:italic> was specifically methylated in the sera of 3\/13 (23%) Hodgkin lymphoma patients.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Conclusions<\/jats:title>\n            <jats:p>Thus, methylation-mediated silencing of <jats:italic>DLEC1<\/jats:italic> plays an important role in multiple lymphomagenesis, and may serve as a non-invasive tumor marker for lymphoma diagnosis.<\/jats:p>\n          <\/jats:sec>","DOI":"10.1186\/1479-5876-10-209","type":"journal-article","created":{"date-parts":[[2012,10,11]],"date-time":"2012-10-11T13:47:21Z","timestamp":1349963241000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":26,"title":["Epigenetic silencing of the 3p22 tumor suppressor DLEC1 by promoter CpG methylation in non-Hodgkin and Hodgkin lymphomas"],"prefix":"10.1186","volume":"10","author":[{"given":"Zhaohui","family":"Wang","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lili","family":"Li","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xianwei","family":"Su","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Zifen","family":"Gao","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Gopesh","family":"Srivastava","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Paul G","family":"Murray","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Richard","family":"Ambinder","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Qian","family":"Tao","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2012,10,11]]},"reference":[{"key":"1358_CR1","doi-asserted-by":"publisher","first-page":"683","DOI":"10.1016\/j.cell.2007.01.029","volume":"128","author":"PA Jones","year":"2007","unstructured":"Jones PA, Baylin SB: The epigenomics of cancer. Cell. 2007, 128: 683-692. 10.1016\/j.cell.2007.01.029.","journal-title":"Cell"},{"key":"1358_CR2","doi-asserted-by":"publisher","first-page":"107","DOI":"10.1038\/nrc1799","volume":"6","author":"SB Baylin","year":"2006","unstructured":"Baylin SB, Ohm JE: Epigenetic gene silencing in cancer - a mechanism for early oncogenic pathway addiction?. Nat Rev Cancer. 2006, 6: 107-116. 10.1038\/nrc1799.","journal-title":"Nat Rev Cancer"},{"key":"1358_CR3","doi-asserted-by":"publisher","first-page":"7283","DOI":"10.1038\/sj.onc.1210547","volume":"26","author":"LB Hesson","year":"2007","unstructured":"Hesson LB, Cooper WN, Latif F: Evaluation of the 3p21.3 tumour-suppressor gene cluster. Oncogene. 2007, 26: 7283-7301. 10.1038\/sj.onc.1210547.","journal-title":"Oncogene"},{"key":"1358_CR4","doi-asserted-by":"publisher","first-page":"3042","DOI":"10.1073\/pnas.95.6.3042","volume":"95","author":"Y Cheng","year":"1998","unstructured":"Cheng Y, Poulos NE, Lung ML, Hampton G, Ou B, Lerman MI, Stanbridge EJ: Functional evidence for a nasopharyngeal carcinoma tumor suppressor gene that maps at chromosome 3p21.3. Proc Natl Acad Sci USA. 1998, 95: 3042-3047. 10.1073\/pnas.95.6.3042.","journal-title":"Proc Natl Acad Sci USA"},{"key":"1358_CR5","first-page":"5775","volume":"53","author":"R Maestro","year":"1993","unstructured":"Maestro R, Gasparotto D, Vukosavljevic T, Barzan L, Sulfaro S, Boiocchi M: Three discrete regions of deletion at 3p in head and neck cancers. Cancer Res. 1993, 53: 5775-5779.","journal-title":"Cancer Res"},{"key":"1358_CR6","first-page":"445","volume":"7","author":"K Hibi","year":"1992","unstructured":"Hibi K, Takahashi T, Yamakawa K, Ueda R, Sekido Y, Ariyoshi Y, Suyama M, Takagi H, Nakamura Y: Three distinct regions involved in 3p deletion in human lung cancer. Oncogene. 1992, 7: 445-449.","journal-title":"Oncogene"},{"key":"1358_CR7","doi-asserted-by":"publisher","first-page":"1273","DOI":"10.1002\/cncr.11621","volume":"98","author":"S Pizzi","year":"2003","unstructured":"Pizzi S, Azzoni C, Bassi D, Bottarelli L, Milione M, Bordi C: Genetic alterations in poorly differentiated endocrine carcinomas of the gastrointestinal tract. Cancer. 2003, 98: 1273-1282. 10.1002\/cncr.11621.","journal-title":"Cancer"},{"key":"1358_CR8","doi-asserted-by":"publisher","first-page":"453","DOI":"10.1007\/s100380200064","volume":"47","author":"Q Yang","year":"2002","unstructured":"Yang Q, Yoshimura G, Mori I, Sakurai T, Kakudo K: Chromosome 3p and breast cancer. J Hum Genet. 2002, 47: 453-459. 10.1007\/s100380200064.","journal-title":"J Hum Genet"},{"key":"1358_CR9","doi-asserted-by":"publisher","first-page":"793","DOI":"10.1002\/cncr.10275","volume":"94","author":"CM Acevedo","year":"2002","unstructured":"Acevedo CM, Henriquez M, Emmert-Buck MR, Chuaqui RF: Loss of heterozygosity on chromosome arms 3p and 6q in microdissected adenocarcinomas of the uterine cervix and adenocarcinoma in situ. Cancer. 2002, 94: 793-802. 10.1002\/cncr.10275.","journal-title":"Cancer"},{"key":"1358_CR10","doi-asserted-by":"publisher","first-page":"59","DOI":"10.1002\/(SICI)1098-2264(199706)19:2<59::AID-GCC1>3.0.CO;2-Z","volume":"19","author":"A van den Berg","year":"1997","unstructured":"van den Berg A, Buys CH: Involvement of multiple loci on chromosome 3 in renal cell cancer development. Genes Chromosomes Cancer. 1997, 19: 59-76. 10.1002\/(SICI)1098-2264(199706)19:2<59::AID-GCC1>3.0.CO;2-Z.","journal-title":"Genes Chromosomes Cancer"},{"key":"1358_CR11","doi-asserted-by":"publisher","first-page":"1090","DOI":"10.1002\/gcc.20495","volume":"46","author":"LR Kimm","year":"2007","unstructured":"Kimm LR, DeLeeuw RJ, Savage KJ, Rosenwald A, Campo E, Delabie J, Ott G, Muller-Hermelink H-K, Jaffe ES, Rimsza LM: Frequent occurrence of deletions in primary mediastinal B-cell lymphoma. Genes Chromosomes Cancer. 2007, 46: 1090-1097. 10.1002\/gcc.20495.","journal-title":"Genes Chromosomes Cancer"},{"key":"1358_CR12","doi-asserted-by":"publisher","first-page":"3497","DOI":"10.1158\/0008-5472.CAN-04-4088","volume":"65","author":"A Agathanggelou","year":"2005","unstructured":"Agathanggelou A, Cooper WN, Latif F: Role of the Ras-association domain family 1 tumor suppressor gene in human cancers. Cancer Res. 2005, 65: 3497-3508. 10.1158\/0008-5472.CAN-04-4088.","journal-title":"Cancer Res"},{"key":"1358_CR13","first-page":"645","volume":"20","author":"R Dammann","year":"2005","unstructured":"Dammann R, Schagdarsurengin U, Seidel C, Strunnikova M, Rastetter M, Baier K, Pfeifer GP: The tumor suppressor RASSF1A in human carcinogenesis: an update. Histol Histopathol. 2005, 20: 645-663.","journal-title":"Histol Histopathol"},{"key":"1358_CR14","doi-asserted-by":"publisher","first-page":"1580","DOI":"10.1038\/sj.onc.1206243","volume":"22","author":"A Agathanggelou","year":"2003","unstructured":"Agathanggelou A, Dallol A, Zochbauer-Muller S, Morrissey C, Honorio S, Hesson L, Martinsson T, Fong KM, Kuo MJ, Yuen PW: Epigenetic inactivation of the candidate 3p21.3 suppressor gene BLU in human cancers. Oncogene. 2003, 22: 1580-1588. 10.1038\/sj.onc.1206243.","journal-title":"Oncogene"},{"key":"1358_CR15","doi-asserted-by":"publisher","first-page":"4793","DOI":"10.1038\/sj.onc.1207632","volume":"23","author":"GH Qiu","year":"2004","unstructured":"Qiu GH, Tan LK, Loh KS, Lim CY, Srivastava G, Tsai ST, Tsao SW, Tao Q: The candidate tumor suppressor gene BLU, located at the commonly deleted region 3p21.3, is an E2F-regulated, stress-responsive gene and inactivated by both epigenetic and genetic mechanisms in nasopharyngeal carcinoma. Oncogene. 2004, 23: 4793-4806. 10.1038\/sj.onc.1207632.","journal-title":"Oncogene"},{"key":"1358_CR16","first-page":"6116","volume":"60","author":"MI Lerman","year":"2000","unstructured":"Lerman MI, Minna JD: identification and evaluation of the resident candidate tumor suppressor genes. the international lung cancer chromosome 3p21.3 tumor suppressor gene consortium. Cancer Res. 2000, 60: 6116-6133.","journal-title":"Cancer Res"},{"key":"1358_CR17","first-page":"2715","volume":"62","author":"L Ji","year":"2002","unstructured":"Ji L, Nishizaki M, Gao B, Burbee D, Kondo M, Kamibayashi C, Xu K, Yen N, Atkinson EN, Fang B: Expression of several genes in the human chromosome 3p21.3 homozygous deletion region by an adenovirus vector results in tumor suppressor activities in vitro and in vivo. Cancer Res. 2002, 62: 2715-2720.","journal-title":"Cancer Res"},{"key":"1358_CR18","doi-asserted-by":"publisher","first-page":"79","DOI":"10.1517\/14796694.1.1.79","volume":"1","author":"L Ji","year":"2005","unstructured":"Ji L, Minna JD, Roth JA: 3p21.3 tumor suppressor cluster: prospects for translational applications. Future Oncol. 2005, 1: 79-92. 10.1517\/14796694.1.1.79.","journal-title":"Future Oncol"},{"key":"1358_CR19","doi-asserted-by":"publisher","first-page":"2408","DOI":"10.1038\/sj.onc.1207407","volume":"23","author":"L Hesson","year":"2004","unstructured":"Hesson L, Bieche I, Krex D, Criniere E, Hoang-Xuan K, Maher ER, Latif F: Frequent epigenetic inactivation of RASSF1A and BLU genes located within the critical 3p21.3 region in gliomas. Oncogene. 2004, 23: 2408-2419. 10.1038\/sj.onc.1207407.","journal-title":"Oncogene"},{"key":"1358_CR20","doi-asserted-by":"publisher","first-page":"289","DOI":"10.1016\/j.lungcan.2006.12.007","volume":"56","author":"Y Wang","year":"2007","unstructured":"Wang Y, Yu Z, Wang T, Zhang J, Hong L, Chen L: Identification of epigenetic aberrant promoter methylation of RASSF1A in serum DNA and its clinicopathological significance in lung cancer. Lung Cancer. 2007, 56: 289-294. 10.1016\/j.lungcan.2006.12.007.","journal-title":"Lung Cancer"},{"key":"1358_CR21","doi-asserted-by":"publisher","first-page":"629","DOI":"10.1016\/j.ygyno.2006.10.003","volume":"104","author":"HC Lai","year":"2007","unstructured":"Lai HC, Lin YW, Chang CC, Wang HC, Chu TW, Yu MH, Chu TY: Hypermethylation of two consecutive tumor suppressor genes, BLU and RASSF1A, located at 3p21.3 in cervical neoplasias. Gynecol Oncol. 2007, 104: 629-635. 10.1016\/j.ygyno.2006.10.003.","journal-title":"Gynecol Oncol"},{"key":"1358_CR22","doi-asserted-by":"publisher","first-page":"1116","DOI":"10.4161\/cbt.4.10.2023","volume":"4","author":"ZG Pan","year":"2005","unstructured":"Pan ZG, Kashuba VI, Liu XQ, Shao JY, Zhang RH, Jiang JH, Guo C, Zabarovsky E, Ernberg I, Zeng YX: High frequency somatic mutations in RASSF1A in nasopharyngeal carcinoma. Cancer Biol Ther. 2005, 4: 1116-1122. 10.4161\/cbt.4.10.2023.","journal-title":"Cancer Biol Ther"},{"key":"1358_CR23","doi-asserted-by":"publisher","first-page":"409","DOI":"10.1002\/path.1784","volume":"206","author":"S Pizzi","year":"2005","unstructured":"Pizzi S, Azzoni C, Bottarelli L, Campanini N, D\u2019Adda T, Pasquali C, Rossi G, Rindi G, Bordi C: RASSF1A promoter methylation and 3p21.3 loss of heterozygosity are features of foregut, but not midgut and hindgut, malignant endocrine tumours. J Pathol. 2005, 206: 409-416. 10.1002\/path.1784.","journal-title":"J Pathol"},{"key":"1358_CR24","doi-asserted-by":"publisher","first-page":"305","DOI":"10.1016\/j.lungcan.2004.05.003","volume":"46","author":"Y Tomizawa","year":"2004","unstructured":"Tomizawa Y, Iijima H, Nomoto T, Iwasaki Y, Otani Y, Tsuchiya S, Saito R, Dobashi K, Nakajima T, Mori M: Clinicopathological significance of aberrant methylation of RARbeta2 at 3p24, RASSF1A at 3p21.3, and FHIT at 3p14.2 in patients with non-small cell lung cancer. Lung Cancer. 2004, 46: 305-312. 10.1016\/j.lungcan.2004.05.003.","journal-title":"Lung Cancer"},{"key":"1358_CR25","doi-asserted-by":"publisher","first-page":"839","DOI":"10.1002\/ijc.20079","volume":"109","author":"LS Chow","year":"2004","unstructured":"Chow LS, Lo KW, Kwong J, To KF, Tsang KS, Lam CW, Dammann R, Huang DP: RASSF1A is a target tumor suppressor from 3p21.3 in nasopharyngeal carcinoma. Int J Cancer. 2004, 109: 839-847. 10.1002\/ijc.20079.","journal-title":"Int J Cancer"},{"key":"1358_CR26","doi-asserted-by":"publisher","first-page":"7862","DOI":"10.1038\/sj.onc.1207082","volume":"22","author":"K Horiguchi","year":"2003","unstructured":"Horiguchi K, Tomizawa Y, Tosaka M, Ishiuchi S, Kurihara H, Mori M, Saito N: Epigenetic inactivation of RASSF1A candidate tumor suppressor gene at 3p21.3 in brain tumors. Oncogene. 2003, 22: 7862-7865. 10.1038\/sj.onc.1207082.","journal-title":"Oncogene"},{"key":"1358_CR27","first-page":"2981","volume":"9","author":"Y Cohen","year":"2003","unstructured":"Cohen Y, Singer G, Lavie O, Dong SM, Beller U, Sidransky D: The RASSF1A tumor suppressor gene is commonly inactivated in adenocarcinoma of the uterine cervix. Clin Cancer Res. 2003, 9: 2981-2984.","journal-title":"Clin Cancer Res"},{"key":"1358_CR28","doi-asserted-by":"publisher","first-page":"7277","DOI":"10.1038\/sj.onc.1205922","volume":"21","author":"KJ Wagner","year":"2002","unstructured":"Wagner KJ, Cooper WN, Grundy RG, Caldwell G, Jones C, Wadey RB, Morton D, Schofield PN, Reik W, Latif F, Maher ER: Frequent RASSF1A tumour suppressor gene promoter methylation in Wilms\u2019 tumour and colorectal cancer. Oncogene. 2002, 21: 7277-7282. 10.1038\/sj.onc.1205922.","journal-title":"Oncogene"},{"key":"1358_CR29","doi-asserted-by":"publisher","first-page":"6835","DOI":"10.1038\/sj.onc.1205814","volume":"21","author":"L Liu","year":"2002","unstructured":"Liu L, Yoon JH, Dammann R, Pfeifer GP: Frequent hypermethylation of the RASSF1A gene in prostate cancer. Oncogene. 2002, 21: 6835-6840. 10.1038\/sj.onc.1205814.","journal-title":"Oncogene"},{"key":"1358_CR30","doi-asserted-by":"publisher","first-page":"1585","DOI":"10.1016\/S0959-8049(01)00422-1","volume":"38","author":"RP Hogg","year":"2002","unstructured":"Hogg RP, Honorio S, Martinez A, Agathanggelou A, Dallol A, Fullwood P, Weichselbaum R, Kuo MJ, Maher ER, Latif F: Frequent 3p allele loss and epigenetic inactivation of the RASSF1A tumour suppressor gene from region 3p21.3 in head and neck squamous cell carcinoma. Eur J Cancer. 2002, 38: 1585-1592. 10.1016\/S0959-8049(01)00422-1.","journal-title":"Eur J Cancer"},{"key":"1358_CR31","doi-asserted-by":"publisher","first-page":"7504","DOI":"10.1073\/pnas.131216298","volume":"98","author":"K Dreijerink","year":"2001","unstructured":"Dreijerink K, Braga E, Kuzmin I, Geil L, Duh FM, Angeloni D, Zbar B, Lerman MI, Stanbridge EJ, Minna JD: The candidate tumor suppressor gene, RASSF1A, from human chromosome 3p21.3 is involved in kidney tumorigenesis. Proc Natl Acad Sci USA. 2001, 98: 7504-7509. 10.1073\/pnas.131216298.","journal-title":"Proc Natl Acad Sci USA"},{"key":"1358_CR32","first-page":"3877","volume":"61","author":"KW Lo","year":"2001","unstructured":"Lo KW, Kwong J, Hui AB, Chan SY, To KF, Chan AS, Chow LS, Teo PM, Johnson PJ, Huang DP: High frequency of promoter hypermethylation of RASSF1A in nasopharyngeal carcinoma. Cancer Res. 2001, 61: 3877-3881.","journal-title":"Cancer Res"},{"key":"1358_CR33","doi-asserted-by":"publisher","first-page":"691","DOI":"10.1093\/jnci\/93.9.691","volume":"93","author":"DG Burbee","year":"2001","unstructured":"Burbee DG, Forgacs E, Zochbauer-Muller S, Shivakumar L, Fong K, Gao B, Randle D, Kondo M, Virmani A, Bader S: Epigenetic inactivation of RASSF1A in lung and breast cancers and malignant phenotype suppression. J Natl Cancer Inst. 2001, 93: 691-699. 10.1093\/jnci\/93.9.691.","journal-title":"J Natl Cancer Inst"},{"key":"1358_CR34","doi-asserted-by":"crossref","first-page":"310","DOI":"10.1038\/sj.onc.1209001","volume":"25","author":"LS Chow","year":"2006","unstructured":"Chow LS, Lam CW, Chan SY, Tsao SW, To KF, Tong SF, Hung WK, Dammann R, Huang DP, Lo KW: Identification of RASSF1A modulated genes in nasopharyngeal carcinoma. Oncogene. 2006, 25: 310-316.","journal-title":"Oncogene"},{"key":"1358_CR35","first-page":"1966","volume":"59","author":"Y Daigo","year":"1999","unstructured":"Daigo Y, Nishiwaki T, Kawasoe T, Tamari M, Tsuchiya E, Nakamura Y: Molecular cloning of a candidate tumor suppressor gene, DLC1, from chromosome 3p21.3. Cancer Res. 1999, 59: 1966-1972.","journal-title":"Cancer Res"},{"key":"1358_CR36","doi-asserted-by":"publisher","first-page":"171","DOI":"10.1002\/gcc.20398","volume":"46","author":"J Kwong","year":"2007","unstructured":"Kwong J, Chow LS, Wong AY, Hung WK, Chung GT, To KF, Chan FL, Daigo Y, Nakamura Y, Huang DP, Lo KW: Epigenetic inactivation of the deleted in lung and esophageal cancer 1 gene in nasopharyngeal carcinoma. Genes Chromosomes Cancer. 2007, 46: 171-180. 10.1002\/gcc.20398.","journal-title":"Genes Chromosomes Cancer"},{"key":"1358_CR37","first-page":"2161","volume":"28","author":"W Ayadi","year":"2008","unstructured":"Ayadi W, Karray-Hakim H, Khabir A, Feki L, Charfi S, Boudawara T, Ghorbel A, Daoud J, Frikha M, Busson P, Hammami A: Aberrant methylation of p16, DLEC1, BLU and E-cadherin gene promoters in nasopharyngeal carcinoma biopsies from Tunisian patients. Anticancer Res. 2008, 28: 2161-2167.","journal-title":"Anticancer Res"},{"key":"1358_CR38","doi-asserted-by":"publisher","first-page":"268","DOI":"10.1593\/neo.05502","volume":"8","author":"J Kwong","year":"2006","unstructured":"Kwong J, Lee JY, Wong KK, Zhou X, Wong DT, Lo KW, Welch WR, Berkowitz RS, Mok SC: Candidate tumor-suppressor gene DLEC1 is frequently downregulated by promoter hypermethylation and histone hypoacetylation in human epithelial ovarian cancer. Neoplasia. 2006, 8: 268-278. 10.1593\/neo.05502.","journal-title":"Neoplasia"},{"key":"1358_CR39","doi-asserted-by":"publisher","first-page":"375","DOI":"10.1038\/sj.bjc.6604452","volume":"99","author":"TJ Seng","year":"2008","unstructured":"Seng TJ, Currey N, Cooper WA, Lee CS, Chan C, Horvath L, Sutherland RL, Kennedy C, McCaughan B, Kohonen-Corish MR: DLEC1 and MLH1 promoter methylation are associated with poor prognosis in non-small cell lung carcinoma. Br J Cancer. 2008, 99: 375-382. 10.1038\/sj.bjc.6604452.","journal-title":"Br J Cancer"},{"key":"1358_CR40","doi-asserted-by":"publisher","first-page":"433","DOI":"10.1016\/j.jhep.2007.11.015","volume":"48","author":"GH Qiu","year":"2008","unstructured":"Qiu GH, Salto-Tellez M, Ross JA, Yeo W, Cui Y, Wheelhouse N, Chen GG, Harrison D, Lai P, Tao Q, Hooi SC: The tumor suppressor gene DLEC1 is frequently silenced by DNA methylation in hepatocellular carcinoma and induces G1 arrest in cell cycle. J Hepatol. 2008, 48: 433-441. 10.1016\/j.jhep.2007.11.015.","journal-title":"J Hepatol"},{"key":"1358_CR41","doi-asserted-by":"publisher","first-page":"663","DOI":"10.1038\/sj.bjc.6604888","volume":"100","author":"J Ying","year":"2009","unstructured":"Ying J, Poon FF, Yu J, Geng H, Wong AH, Qiu GH, Goh HK, Rha SY, Tian L, Chan AT: DLEC1 is a functional 3p22.3 tumour suppressor silenced by promoter CpG methylation in colon and gastric cancers. Br J Cancer. 2009, 100: 663-669. 10.1038\/sj.bjc.6604888.","journal-title":"Br J Cancer"},{"key":"1358_CR42","doi-asserted-by":"publisher","first-page":"731","DOI":"10.1016\/j.juro.2010.03.108","volume":"184","author":"Q Zhang","year":"2010","unstructured":"Zhang Q, Ying J, Li J, Fan Y, Poon FF, Ng KM, Tao Q, Jin J: Aberrant promoter methylation of DLEC1, a critical 3p22 tumor suppressor for renal cell carcinoma, is associated with more advanced tumor stage. J Urol. 2010, 184: 731-737. 10.1016\/j.juro.2010.03.108.","journal-title":"J Urol"},{"key":"1358_CR43","doi-asserted-by":"publisher","first-page":"73","DOI":"10.1007\/s00428-010-1013-6","volume":"458","author":"SY Park","year":"2010","unstructured":"Park SY, Kwon HJ, Lee HE, Ryu HS, Kim SW, Kim JH, Kim IA, Jung N, Cho NY, Kang GH: Promoter CpG island hypermethylation during breast cancer progression. Virchows Arch. 2010, 458: 73-84.","journal-title":"Virchows Arch"},{"key":"1358_CR44","doi-asserted-by":"publisher","first-page":"161","DOI":"10.1038\/labinvest.3700707","volume":"88","author":"GH Kang","year":"2008","unstructured":"Kang GH, Lee S, Cho NY, Gandamihardja T, Long TI, Weisenberger DJ, Campan M, Laird PW: DNA methylation profiles of gastric carcinoma characterized by quantitative DNA methylation analysis. Lab Invest. 2008, 88: 161-170. 10.1038\/labinvest.3700707.","journal-title":"Lab Invest"},{"key":"1358_CR45","doi-asserted-by":"publisher","first-page":"21","DOI":"10.1016\/j.canlet.2010.12.011","volume":"303","author":"Y Zhang","year":"2011","unstructured":"Zhang Y, Wang R, Song H, Huang G, Yi J, Zheng Y, Wang J, Chen L: Methylation of multiple genes as a candidate biomarker in non-small cell lung cancer. Cancer Lett. 2011, 303: 21-28. 10.1016\/j.canlet.2010.12.011.","journal-title":"Cancer Lett"},{"key":"1358_CR46","doi-asserted-by":"publisher","first-page":"15","DOI":"10.4161\/epi.2.1.3883","volume":"2","author":"J Ying","year":"2007","unstructured":"Ying J, Li H, Murray P, Gao Z, Chen YW, Wang Y, Lee KY, Chan AT, Ambinder RF, Srivastava G, Tao Q: Tumor-specific methylation of the 8p22 tumor suppressor gene DLC1 is an epigenetic biomarker for Hodgkin, nasal NK\/T-cell and other types of lymphomas. Epigenetics. 2007, 2: 15-21. 10.4161\/epi.2.1.3883.","journal-title":"Epigenetics"},{"key":"1358_CR47","doi-asserted-by":"publisher","first-page":"1480","DOI":"10.2353\/ajpath.2010.100052","volume":"177","author":"PG Murray","year":"2010","unstructured":"Murray PG, Fan Y, Davies G, Ying J, Geng H, Ng KM, Li H, Gao Z, Wei W, Bose S: Epigenetic silencing of a proapoptotic cell adhesion molecule, the immunoglobulin superfamily member IGSF4, by promoter CpG methylation protects Hodgkin lymphoma cells from apoptosis. Am J Pathol. 2010, 177: 1480-1490. 10.2353\/ajpath.2010.100052.","journal-title":"Am J Pathol"},{"key":"1358_CR48","doi-asserted-by":"publisher","first-page":"4130","DOI":"10.1182\/blood-2007-06-094870","volume":"110","author":"J Ying","year":"2007","unstructured":"Ying J, Li H, Chen YW, Srivastava G, Gao Z, Tao Q: WNT5A is epigenetically silenced in hematologic malignancies and inhibits leukemia cell growth as a tumor suppressor. Blood. 2007, 110: 4130-4132. 10.1182\/blood-2007-06-094870.","journal-title":"Blood"},{"key":"1358_CR49","doi-asserted-by":"publisher","first-page":"1070","DOI":"10.1038\/sj.onc.1209154","volume":"25","author":"J Ying","year":"2006","unstructured":"Ying J, Li H, Seng TJ, Langford C, Srivastava G, Tsao SW, Putti T, Murray P, Chan AT, Tao Q: Functional epigenetics identifies a protocadherin PCDH10 as a candidate tumor suppressor for nasopharyngeal, esophageal and multiple other carcinomas with frequent methylation. Oncogene. 2006, 25: 1070-1080. 10.1038\/sj.onc.1209154.","journal-title":"Oncogene"},{"key":"1358_CR50","doi-asserted-by":"publisher","first-page":"1326","DOI":"10.1038\/sj.onc.1207313","volume":"23","author":"PG Murray","year":"2004","unstructured":"Murray PG, Qiu GH, Fu L, Waites ER, Srivastava G, Heys D, Agathanggelou A, Latif F, Grundy RG, Mann JR: Frequent epigenetic inactivation of the RASSF1A tumor suppressor gene in Hodgkin\u2019s lymphoma. Oncogene. 2004, 23: 1326-1331. 10.1038\/sj.onc.1207313.","journal-title":"Oncogene"},{"key":"1358_CR51","doi-asserted-by":"publisher","first-page":"6516","DOI":"10.1158\/0008-5472.CAN-09-4566","volume":"70","author":"Y Cheng","year":"2010","unstructured":"Cheng Y, Geng H, Cheng SH, Liang P, Bai Y, Li J, Srivastava G, Ng MH, Fukagawa T, Wu X: KRAB zinc finger protein ZNF382 is a proapoptotic tumor suppressor that represses multiple oncogenes and is commonly silenced in multiple carcinomas. Cancer Res. 2010, 70: 6516-6526. 10.1158\/0008-5472.CAN-09-4566.","journal-title":"Cancer Res"},{"key":"1358_CR52","doi-asserted-by":"publisher","first-page":"12353","DOI":"10.1073\/pnas.0700153104","volume":"104","author":"H Jin","year":"2007","unstructured":"Jin H, Wang X, Ying J, Wong AH, Cui Y, Srivastava G, Shen ZY, Li EM, Zhang Q, Jin J: Epigenetic silencing of a Ca(2+)-regulated Ras GTPase-activating protein RASAL defines a new mechanism of Ras activation in human cancers. Proc Natl Acad Sci USA. 2007, 104: 12353-12358. 10.1073\/pnas.0700153104.","journal-title":"Proc Natl Acad Sci USA"},{"key":"1358_CR53","doi-asserted-by":"crossref","first-page":"7075","DOI":"10.1128\/JVI.72.9.7075-7083.1998","volume":"72","author":"Q Tao","year":"1998","unstructured":"Tao Q, Robertson KD, Manns A, Hildesheim A, Ambinder RF: The Epstein-Barr virus major latent promoter Qp is constitutively active, hypomethylated, and methylation sensitive. J Virol. 1998, 72: 7075-7083.","journal-title":"J Virol"},{"key":"1358_CR54","doi-asserted-by":"publisher","first-page":"619","DOI":"10.1016\/S0002-9440(10)65157-7","volume":"155","author":"Q Tao","year":"1999","unstructured":"Tao Q, Swinnen LJ, Yang J, Srivastava G, Robertson KD, Ambinder RF: Methylation status of the Epstein-Barr virus major latent promoter C in iatrogenic B cell lymphoproliferative disease. Application of PCR-based analysis. Am J Pathol. 1999, 155: 619-625. 10.1016\/S0002-9440(10)65157-7.","journal-title":"Am J Pathol"},{"key":"1358_CR55","doi-asserted-by":"publisher","first-page":"e7089","DOI":"10.1371\/journal.pone.0007089","volume":"4","author":"S Toujani","year":"2009","unstructured":"Toujani S, Dessen P, Ithzar N, Danglot G, Richon C, Vassetzky Y, Robert T, Lazar V, Bosq J, Da Costa L: High resolution genome-wide analysis of chromosomal alterations in Burkitt\u2019s lymphoma. PLoS One. 2009, 4: e7089-10.1371\/journal.pone.0007089.","journal-title":"PLoS One"}],"container-title":["Journal of Translational Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/1479-5876-10-209.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,9,1]],"date-time":"2021-09-01T21:39:07Z","timestamp":1630532347000},"score":1,"resource":{"primary":{"URL":"https:\/\/translational-medicine.biomedcentral.com\/articles\/10.1186\/1479-5876-10-209"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2012,10,11]]},"references-count":55,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2012,12]]}},"alternative-id":["1358"],"URL":"https:\/\/doi.org\/10.1186\/1479-5876-10-209","relation":{},"ISSN":["1479-5876"],"issn-type":[{"value":"1479-5876","type":"electronic"}],"subject":[],"published":{"date-parts":[[2012,10,11]]},"assertion":[{"value":"22 July 2012","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"4 October 2012","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"11 October 2012","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}}],"article-number":"209"}}